NCT01432262

13-valent Pneumococcal Conjugate Vaccine Study in Adults => 50 Years of Age in Mexico

A Phase 3, Open Label, Single Arm, Multicenter, Trial to Assess The Safety, Tolerability And Immunogenicity Of 13-Valent Pneumococcal Conjugate Vaccine In Healthy Adults Aged => 50 Years of Age Who Are Naive To 23-Valent Pneumococcal Polysaccharide Vaccine in Mexico.

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 324 (actual)
• Sponsor: Pfizer · Industry
• Sex: All
• Age: 50 Years
• Healthy volunteers: Accepted

Summary

The purpose of this study will be to assess the safety, tolerability, and immunogenicity of 13-Valent Pneumococcal Conjugate Vaccine (13vPnC) when given to healthy adults older than 50 years of age who haven't received 23-valent pneumococcal polysaccharide vaccine in Mexico.

Conditions

• Pneumococcal Infections

Interventions

Type	Name	Description
BIOLOGICAL	vaccine-13vPnC	Single dose of 0.5 ml of 13vPnC administered in deltoid muscle of arm at visit 1 (day 1)
BIOLOGICAL	vaccine-13vPnC	Single dose of 0.5 ml of 13vPnC administered in deltoid muscle of arm at visit 1 (day 1)

Timeline

• Start date: 2011-07-01
• Primary completion: 2011-12-01
• Completion: 2011-12-01
• First posted: 2011-09-12
• Last updated: 2013-01-25
• Results posted: 2013-01-08

Locations

4 sites across 1 country: Mexico